


## Participant Flow



## Baseline Characteristics

Participant	Sex	Age	Disorder Subtype	Co-occurring Diagnoses
01F	F	8;8	inconsistent phonological disorder	Developmental Language Disorder
03F	F	10;11	childhood apraxia of speech	Developmental Coordination Disorder
04M	M	7;2	phonological delay	
05M	M	6;5	phonological disorder	Developmental Language Disorder
06M	M	6;4	phonological delay	
07M	M	8;11	childhood apraxia of speech	
08M	M	10;2	childhood apraxia of speech	Autism
10M	M	13;4	childhood apraxia of speech	
11M	M	6;7	phonological delay	
15M	M	6;1	phonological delay	
16M	M	7;7	articulation disorder	
17M	M	13;2	phonological delay	Sensory Processing Disorder/Autism
18F	F	7;1	articulation disorder	Autism
19M	M	10;0	phonological delay	
20M	M	9;2	articulation disorder	
MEAN	M=12	8.77		
SD		2.37		

## Outcome measures

### *Primary outcome measure*

Intelligibility measured using the Intelligibility in Context Scale. Table shows the Intelligibility in Context Scale results and improvements in raw score.

Participant	BL1	Post	Maint	Improvement Post-BL1	Improvement Main-BL2
<b>01F</b>	3.6	3.3		-0.3	
<b>03F</b>	3.1	2.9	3.4	-0.3	0.3
<b>04M</b>	4.0	5.0	4.0	1.0	0.0
<b>05M</b>	3.6	4.0	4.1	0.4	0.6
<b>06M</b>	3.7	4.9	4.9	1.1	1.1
<b>07M</b>	2.6	3.4		0.9	-2.6
<b>08M</b>	3.4	3.3	3.0	-0.1	-0.4
<b>10M</b>	3.4	3.6	3.6	0.1	0.1
<b>11M</b>	3.1	3.4	3.4	0.3	0.3
<b>15M</b>	3.1	4.0	4.6	0.9	1.4
<b>16M</b>	3.6	3.7	4.6	0.1	1.0
<b>17M</b>	3.4	3.3	3.1	-0.1	-0.3
<b>18F</b>	2.7	3.4	3.4	0.7	0.7
<b>19M</b>	3.1	3.9	3.9	0.7	0.7
<b>20M</b>	2.3	2.7		0.4	

## Secondary outcome measures

Accuracy of speech production measured using probe word lists.

Participant	% Targeted Segments Correct At Each Time Point						<i>d</i>
	Baseline 1	Baseline 2	Baseline 3	Mid-Intervention	Post-Intervention	3-Months Post	
<b>01F</b>	12.2	17.1	3.7	9.8	22.0		1.0
<b>03F</b>	1.2	2.4	1.2	18.3	29.3	59.8	7.2
<b>04M</b>	1.2	2.4	6.1	41.5	54.9	61.0	10.3
<b>05M</b>	10.0	15.0	5.0	90.0	35.0	100.0	13.6
<b>06M</b>	0.0	2.4	0.0	0.0	61.9	88.1	10.3
<b>07M</b>	7.1	16.7	9.5	33.3	88.1		10.4
<b>08M</b>	0.0	0.0	0.0	1.7	32.0	37.1	4.9
<b>10M</b>	3.1	2.0	2.0	2.0	3.1	2.0	0.0
<b>11M</b>	0.0	2.4	1.2	1.2	0.0	0.0	-0.2
<b>15M</b>	1.2	9.8	0.0	8.5	41.5	81.7	8.4
<b>16M</b>	0.0	0.0	0.0	32.7	87.8	72.4	13.5
<b>17M</b>	1.2	2.4	0.0	2.4	18.3	17.1	2.4
<b>18F</b>	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>19M</b>	2.4	9.5	7.1	64.3	69.0	28.6	10.0
<b>20M</b>	2.0	8.2	0.0	0.0	3.1		-0.4
<b>MEAN</b>	2.8	6.0	2.4	20.4	36.4	45.6	6.7

*d*= Standard Mean Difference

**Adverse events**

There were no adverse events associated with this trial.